期刊名称：HPB
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
HPB is an international forum for clinical, scientific and educational communication.
Ten issues a year bring the reader leading articles, expert reviews, original articles, images, editorials, and reader correspondence encompassing all aspects of benign and malignant hepatobiliary disease and its management. HPB features relevant aspects of clinical and translational research and practice.
Specific areas of interest include HPB diseases encountered globally by clinical practitioners in this specialist field of gastrointestinal surgery. The journal addresses the challenges faced in the management of cancer involving the liver, biliary system and pancreas. While surgical oncology represents a large part of HPB practice, submission of manuscripts relating to liver and pancreas transplantation, the treatment of benign conditions such as acute and chronic pancreatitis, and those relating to hepatobiliary infection and inflammation are also welcomed. There will be a focus on developing a multidisciplinary approach to diagnosis and treatment with endoscopic and laparoscopic approaches, radiological interventions and surgical techniques being strongly represented.
HPB aims to help its readers - surgeons, physicians, radiologists and basic scientists - to develop their knowledge and practice. HPB will be of interest to specialists involved in the management of hepatobiliary and pancreatic disease however will also inform those working in related fields.
Indexed / Abstracted in
MEDLINE (NLM)
Science Citation Index Expanded™ (Thomson Reuters)
Web of Science (Thomson Reuters)
Instructions to Authors
HPB publishes original articles, reviews, meta-analyses, systematic reviews and randomized clinical trials, all of which are submitted to rigorous peer review. HPB subscribes to the policies published by the International Committee of Medical Journal Editors (ICMJE) and adheres to publishing ethics guidelines published by the Committee on Publication Ethics (COPE). HPB now requires Corresponding Authors to complete an Author statement on behalf of all co-authors before acceptance of the manuscript. The Author Statement form can be found here; copies may also be requested from the Editorial Office.
1. Important information for Authors
An article is reviewed for publication on the assumption that its contents have not been submitted simultaneously to another journal, have not been accepted for publication elsewhere and have not already been published; authors will be asked to confirm that this is the case during the electronic submission process. Any attempt at dual publication will lead to automatic rejection, may prejudice acceptance of future submissions, and may be highlighted within the pages of the Journal. Please submit with your manuscript copies of any other papers (including abstracts) - published, in press, or submitted for consideration elsewhere - that relate in whole or in part to the same data set; this is essential to enable assessment of any potential overlap by the Editors. Indicate on the title page whether the paper is based on a previous communication to a society or meeting.
Articles and their illustrations become the property of the Journal unless rights are reserved before publication.
2. Article types
Please note that HPB does not publish case studies.
a) Leading articles
The Editors commission leading articles of 800-1000 words and up to ten references. A single author is preferred. Submissions may be subjected to peer review and the Editors retain the right to alter textual style.
b) Reviews (including systematic reviews and meta-analyses)
Priority will be given to work that addresses a topic of current interest. All meta-analyses of randomized trials must adhere to the guidelines outlined in the QUOROM statement, which is designed to improve manuscript quality. Authors must include a suitable QUOROM flow chart in their submission (click here for a template). Further advice on suitability is available from the Editor-in-Chief (ojgarden@ed.ac.uk).
Useful resources for Authors of review articles include the article 'Systematic reviews and meta-analysis for the surgeon scientist' by Galandiuk and colleagues, and the Cochrane Handbook for Systematic Reviews of Interventions.
HPB will consider for publication Cochrane review articles that have been substantially shortened and re-written for a surgical audience, but such submissions must state this on the title page of the manuscript, and copies of the original article must be sent to the editorial office for consideration. You must also apply for permission from the Cochrane Library - further information on how to do this is available in the Cochrane Manual. These articles will be subject to the usual HPB peer review process.
c) Prospective clinical trials
HPB expects all authors to register prospective clinical trials in a suitable electronic and freely accessible registry (e.g. www.clinicaltrials.gov, www.controlled-trials.com), according to the ICMJE guidelines1,8. For this purpose, a clinical trial is defined as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between an intervention and a health outcome. The registration number of the clinical trial should be quoted at the end of the abstract. If you wish the Editor to consider an unregistered trial, please explain why the trial has not been registered.
In addition, all randomized clinical trials must adhere to the guidelines outlined in the CONSORT statement and investigators must include a suitable CONSORT flow chart in their submission (click here for a template). The primary end point and power calculation must be clearly stated, and randomized clinical trials should be clearly identified as such in both the title and the abstract.
d) Original articles
Original articles should normally be in the format of Introduction, Methods, Results and Discussion. A structured abstract of fewer than 200 words should be provided (further details on this can be found below).
e) Correspondence
The Editors welcome topical correspondence from readers relating to articles published in the Journal. Letters must be no more than 250 words in length, including no more than 5 references.
f) Invited Commentary
The Editors may seek an invited commentary which will accompany a topical original article. This should normally be fewer than 500 words with no more than 5 references. The Editors retain the right to alter textual style.
h) Guidelines
Guidelines that accompany an article may be considered for publication in the journal. If you intend to prepare guidelines from a consensus meeting and are interested in submitting them to the journal please consult with the Editor-in-Chief (ojgarden@ed.ac.uk) in the first instance.
3. Preparation of manuscripts
HPB subscribes to the policy of uniform requirements for manuscripts; this facilitates resubmission of papers to journals without extensive recasting. Authors are advised to consult the Uniform Requirements for Manuscripts Submitted to Biomedical Journals. HPB accepts the criteria for authorship proposed in the ICMJE 1, 10 and subscribes to the COPE guidelines on good publication practice 2. These guidelines are summarised below.
a) Authorship
For research papers, Authorship should be decided at the launch of the study. The Authorship credit should be based on 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3.
Contributors who do not qualify as Authors should be listed and their particular contribution described in the Acknowledgements section of the article. On submission of the article, the corresponding author will be asked to confirm how all individuals listed as Authors meet the appropriate authorship criteria, that no-one who qualifies for authorship has been omitted from the list, that written authorization has been received from all co-authors, that contributors and all funding sources (for Authors and Contributors) have been properly acknowledged and that authors and contributors have approved the acknowledgement of their contribution.
The corresponding author is responsible for ensuring that all authors have seen, approved and are fully conversant with the contents of the manuscript. All authors are responsible for the accuracy of the manuscript, including all statistical calculations and drug doses.
b) Group authorship
Results of multicentre studies may be reported under the name of the organizing group; however, the group should identify individuals who accept direct responsibility for the manuscript. These individuals should meet the criteria for authorship described above. The individual authors who accept direct responsibility for the manuscript should list the members of the larger authorship group in an appendix to their acknowledgements.
c) Contributors
Authors must acknowledge any assistance that they received (e.g. provision of writing assistance, literature searching, data analysis, administrative support, supply of materials). If/how this assistance was funded should be described and included with other funding information. Written approval should be obtained from anybody listed in acknowledgements, as readers may infer their endorsement of the data and conclusions.
4. Submission guidelines
a) Preferred file formats
Preferred file formats for text and tables are .doc or .rtf. Figures should be .tiff or .eps. Please note: HPB does not accept Microsoft 2007 documents at this time - use the "Save As" option in Word to save your document as an older (.doc) file type. Other restricted file extensions are .shs, .zip, .exe, .com, .vbs and .pdf.
b) Title page
On the title page please state: (1) the title of the article; (2) the name and initials of each author; (3) the department(s) and institution(s) to which the work should be attributed; (4) the name, postal and e-mail addresses, telephone and facsimile numbers of the author responsible for correspondence and to whom requests for reprints should be addressed; (5) sources of funding for research and/or publication; (6) the category in which the manuscript is being submitted (original article, review, randomized clinical trial); and (7) whether the paper is based on a previous communication to a society or meeting (with full details).
c) Abstract
This must contain fewer than 200 words in a structured format. Background: state why the study was done, the main aim and the nature of the study (randomized clinical trial, retrospective review, experimental study etc.). Methods: describe patients, laboratory material and other methods used. Results: state the main findings, including important numerical values. Discussion: state the main conclusions, highlighting controversial or unexpected observations. A list of Keywords must be placed after this section.
d) Main text
The main text of the paper may have separate Introduction, Methods, Results and Discussion sections (these sections may not be applicable to all article types, e.g. reviews). A short Acknowledgements paragraph may also be included and appropriate keywords should be provided. When quoting specific materials, equipment and proprietary drugs, the name and address of the manufacturer must be given in parentheses. Generic names should normally be used. Any data mentioned in the abstract or discussion must be presented in the results section of the main text.
It is appreciated that there are a variety of writing styles, but the HPB editorship would like to ensure a degree of uniformity in the presentation of the manuscript. Ensure that the Abstract describes the content of the manuscript accurately. The Abstract may be all that is seen when a search engine is used and will draw potential readers to the contents of the main article. The Introduction should be focused and brief, putting the current study into context. Methodology and Results sections should be well structured and should avoid redundancy. If tables are used, avoid repetition of results in the text. Avoid the use of personal pronouns and ensure that patients are not referred to as 'cases'. The Discussion should focus on the results of the study and discuss these in the context of the existing literature. Highlight those areas of the study that bring new information to the reader.
e) Tables and illustrations
Submit each illustration as a separate file except compound figures e.g. 1a, 1b, 1c etc, which should be supplied as a single file. Type each table on a separate page with a brief title. Supply artwork at the intended size for printing. Line drawings are acceptable as clear black on white graphics and must be high quality. Use hatchings, not tints. All illustrations must be supplied at the correct resolution:
1200 dpi (dots per inch) for black and white line art (simple bar graphs, etc.)
300 dpi for halftones (black and white photographs)
600 dpi for combination halftones (photographs that also contain line art such as labelling or thin lines)
Illustrations in colour are encouraged and will be printed at no cost to the author. Label each illustration with the figure number and lead author's name. Indicate the top of the illustration and a measure of magnification for photomicrographs. Include explanations of symbols and shading within the figure, use arrows to identify particular areas of interest. Survival curves must be accompanied by a table giving the actual numbers of patients involved and should be truncated when the numbers at risk are small; that is, when they are less than one-third of the starting figure. Include in the legends to illustrations, and the footnotes to tables, brief but comprehensive explanations of all the information presented. Look at recent issues of the Journal for examples of accepted layout.
f) Abbreviations
Avoid using abbreviations. Terms that are mentioned frequently may be abbreviated but only if this does not impair comprehension. Abbreviations must be used consistently and must be defined on first use.
g) Numbers and units
Provide absolute numbers always; percentages may be given in addition but never on their own (percentages are not acceptable for sample sizes less than 50). Use the decimal point, not a comma; for example 5.7. Use a space and not a comma after thousands and multiples thereof; for example 10 000. Use SI units (International System of Units) except for the measurement of blood pressure (mmHg).
h) Statistics and design
Set out clearly the objectives of the study; identify the primary and secondary hypotheses, the chosen end-points and justify the sample size with a power calculation.
Clearly describe methods used for analysis; methods not in common usage should be referenced. Report results of statistical tests by stating the value of the test statistic, the number of degrees of freedom and the P value. Actual P values should always be reported to three decimal places, especially when the result is not significant. The results of the primary analyses should be reported using confidence intervals instead of, or in addition to, P values. For detailed guidance on the handling of statistical material consult the article by Murray 11.
i) Expression of data
All results should be presented as actual numbers.
For nominal data with denominators greater than 50, percentages should be given to 1 decimal place.
For continuous data non parametric descriptors (median and range) and statistical analysis (e.g. Mann Whitney U) should be performed unless it can be shown (statistically) that data are normally distributed in which case it is reasonable to use parametric tests (e.g. student t-test).
Extensive use of tables is encouraged and data provided in tables should not be repeated in text. All tables, figures and graphs must have a stand alone legend which enables interpretation without the need to refer to the text.
P values should be standardised to 3 decimal places and should include actual values for those values that are non-significant.
For Kaplan-Meier curves the following should be adhered to:
a) Numbers at risk should be given below the x-axis in line with the time value.
b) Each individual graph should be truncated when the number at risk reaches the greater of either 1/10th of the original denominator or 5.
c) Censored variables should be shown
j) References
Use double spacing in the Vancouver style. Reference to abstracts and personal communications is discouraged. In the text, number references consecutively by superscript: e.g. 1 or 1-3. References cited only in tables or figures should be numbered in sequence.
5. Copyright and permissions (Ownership)
Authors must declare that the submitted work is their own and that copyright has not been breached in seeking its publication. Before publication, therefore, a copyright transfer agreement signed by all authors is required. In addition, it is the authors' responsibility to obtain written permission to reproduce (in all media, including electronic) any material that has appeared previously in another publication. Authors should provide copies of permission letters for any material reproduced from copyrighted publications. Submitted material will not be returned to the author unless specifically requested.
The CTA can be found here and a permissions request form can be found here. Alternatively, both forms may be requested from the Editorial Office. Completed and signed CTA and permission forms can be scanned and uploaded in the "Other" section of HPB Manuscript Central or faxed to the editorial office (telephone number shown below). Alternatively original copies can be sent immediately following the online submission of your article, addressed to the publisher:
HPB Editorial Office
Wiley-Blackwell
The Atrium
Southern Gate
Chichester
PO19 8SQ
United Kingdom
Email: HPBedoffice@wiley.com
6. Research ethics
Human investigation and animal experiments must have local ethics committee approval and, if human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Written consent must be obtained from the patient (legal guardian or executor, if appropriate) for publication of any detail or photograph that might identify an individual. Submit evidence of such consent with the manuscript.
Editors reserve the right to reject papers if there is doubt whether appropriate procedures have been followed.
7. Publication ethics
a) Originality
On submission of the manuscript the corresponding author must warrant that the article is an original work, has not been published before, and is not being considered for publication elsewhere in its final form, in either printed or electronic media.
Publication of abstracts and presentations at scientific meetings will not jeopardise full publication. Authors should declare that any republication of the data (e.g. in secondary analysis or translation) will not constitute redundant publication, will not breach copyright, and will reference the original publication.
b) Redundant (multiple) publication
HPB does not consider the following to be prior publication: abstracts and posters at conferences, results presented at meetings (for example, to inform investigators or participants about findings) and results databases (data without interpretation, discussion, context or conclusions in the form of tables and text to describe data/information where this is not easily presented in tabular form). Manuscripts that have been published previously in another language should state this on the title page of the submission. Manuscripts that have been previously published in English that are submitted with the aim of serving different audiences are not generally accepted by HPB (an exception to this is the publication of substantially shortened Cochrane Review articles; see section 2.b).
Editors may request copies of related publications if they are concerned about overlap and possible redundancy.
Sub-group analyses, meta-, and secondary analyses should be clearly identified as analyses of data that have already been published, and must refer to the primary source.
c) Conflict of interest statements
All authors must provide details of financial interests (including employment, significant share ownership, patent rights, consultancy, research funding, speaker's fees) in an company or institution that might benefit from the publication of the submitted article. In addition, authors must provide details of any other potential competing interests that readers or editors might consider relevant to their publication (for example, political, intellectual, or religious interests).
d) Research and publication misconduct
HPB adheres to COPE guidelines[ii] and will pursue cases of suspected research and publication misconduct (including falsification, fabrication, plagiarism, inappropriate image manipulation, redundant publication and authorship misdemeanours). In such cases, HPB will follow the processes set out in the COPE flowcharts12. Authors found guilty of misconduct can expect their behaviour to be reported to the head of the relevant institution, and details of the case may be highlighted in the pages of the journal13. If you have concerns regarding the legitimacy of an article published in HPB, please write to the Editor-in-Chief at ojgarden@ed.ac.uk.
e) Research or publication funding
Authors must disclose all sources of funding for their research and its publication on the title page of the manuscript. Involvement of the funder in study design, data collection, data analysis, manuscript preparation and publication decisions should be clearly stated, and Authors are also asked to confirm that they had complete access to the study data that support the publication.
8. Manuscript submission
HPB operates an online submission and peer review system that enables authors to submit articles online and track their progress via a web interface. Any queries regarding Manuscript Central or manuscript submission should be directed to the HPB Editorial Office (HPBedoffice@wiley.com).
Manuscripts should be submitted online at http://mc.manuscriptcentral.com/hpb
Authors whose first language is not English may wish to consult a specialist English Language editing/proofing service before submission. Please contact the HPB Editorial Office if you would like to receive the details of such services.
9. Author resources
http://olabout.wiley.com/WileyCDA/Section/id-404516.html
From the Publishers of HPB, Author Resources offers a full menu of customizable research capabilities and special features to guide Authors through every stage of the publication process. Available tools include: Citation Download - download citations and abstracts directly into reference management software; Citation Tracking - see which other papers have cited the article that you're currently reading, ToC Alerts - sign up to receive tables of content from selected journals; Saved Search Alerts - store and re-run detailed search queries, and opt to receive an email each time new content matching your defined search is published online. In addition, the 'Track my Articles' function enables Authors to track articles through the HPB publication process and opt-in to receive email notification when their article is published online.
10. Peer review and editing
On submission of a manuscript for publication, the submission is checked for compliance with these author instructions. If the submission is complete, the Editor-in-Chief assesses the manuscript for suitability. A small percentage of manuscripts are rejected without peer review at this stage; for example, if the article type is inappropriate (for example, HPB does not publish case reports), if the subject matter is unsuitable for the HPB readership (for example, 'A new method of internal fixation of fractures of the fibula'), or if the scientific and/or surgical merit of the paper is flawed (for example, if it is not ethical). All other articles are allocated to a specialist Editor, who either selects relevant referees for single-blind peer-review (the referees know the identity of the authors, but the authors do not know the identity of the referees) or consults with at least one other Editor before rejecting the manuscript without peer review (for the reasons outlined above).
This 'triage' system of rejecting a small percentage of manuscripts without peer review serves two purposes. Firstly, quick decisions on papers unsuitable for HPB facilitate submission to another Journal in a timely fashion and, secondly, the Journal's most valuable asset - the referees - are not overloaded with manuscripts that will not be accepted for publication.
Three referees are usually invited to comment on each submission; if the first two referee reports are in agreement the Editor, a decision is made on the basis of two reports, hopefully saving the third referee some valuable time. When the opinions of the referees differ significantly, the manuscript is discussed by the Editors. When a decision has been reached this is communicated to the Author.
Articles not subjected to peer review include solicited leading articles, in which case the topic and structure of the article is largely designed by the Editor-in-Chief in collaboration with the author, the correspondence section, book reviews, all of which are overseen to the highest standards by a dedicated HPB Editor.
The Editors' decision is final unless there is proven to be an error in the process of manuscript evaluation or peer review. If you believe that there has been an error of process in the handling of your manuscript, please address your concerns to the Editor-in-Chief at ojgarden@ed.ac.uk, quoting the manuscript submission number.
11. Proofing
On acceptance of a manuscript it is edited by both an Editor and a copy editor before being sent for typesetting. If there are extensive queries at this stage, the Authors may be asked to provide clarification before the typesetting process. Proofs are sent approximately 6-8 weeks after acceptance via e-mail as a link to a PDF file. Acrobat Reader will be required in order to read this file - this software can be downloaded free of charge. Further instructions will be sent with the proof. Absent authors should arrange for a colleague to access the e-mail to retrieve the proof.
12. References
1. International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication. http:// www.icmje.org [accessed 13 January 2009].
2. The Committee on Publication Ethics. http:// www.publicationethics.org.uk [accessed 13 January 2009].
3. Polk H, Bowden T, Rikkers L, et al. Consensus Statement on Submission and Publication of Manuscripts. Ann Surg Oncol 2001; 8: 382-34. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999; 354 : 1896-1900.
5. Sauerland S, Seiler CM, Role of Systematic Reviews and Meta-analysis in Evidence-based Medicine. World J Surg 2005; 29(5):582-76. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions (formerly the Reviewers' Handbook). http:// www.cochrane.org/resources/handbook/ [accessed 13 January 2009].
7. The Cochrane Collaboration. The Cochrane Manual Issue 3 2007 [updated 24 May 2007] ( http://www.cochrane.org/admin/manual.htm ) [accessed 13 January 2009].
8. Surgical Journal Editors Group. Consensus statement on mandatory registration of clinical trials. Ann Surg. 2007; 245(4): 505-506
9. CONSORT. www.consort-statement.org [accessed 13 January 2009].
10. Surgical Journal Editors Group. Consensus statement on surgery journal authorship. Ann Thorac Surg 2006; 81(6); 2343-4.
11. D G Altman, S M Gore, M J Gardner, and S J Pocock. Statistical Guidelines for Contributors to Medical Journals. Br Med J (Clin Res Ed). 1983; 286(6376); 1489-1493.
12. Committee on Publication Ethics Flowcharts. http://publicationethics.org/flowcharts [accessed 13 January 2009].
13. Murie JA, Sarr MG, Warshaw AL: A tale of three papers. Br J Surg 2006, 93: 1560-1562.
14. Surgical Journal Editors Group. Scientific data from clinical trials: investigators' responsibilities and rights. Am J Surg. 2002;183(6):605-6.
Editorial Board
Editor-in-Chief
O James Garden, Edinburgh, UK
Associate Editors
Mark Callery, Boston, USA
Saxon Connor, Christchurch, New Zealand
Stephen J Wigmore, Edinburgh, UK
Honorary Regional Editors
Yuji Nimura, Nagoya, Japan
Huug Obertop, Amsterdam, the Netherlands
Steve Strasberg, St Louis, USA
Editorial Board
Peter Allen, USA
Claudio Bassi, Verona, Italy
Kevin E Behrns, USA
Jacques Belghiti, Beaujon, France
Giulio Belli, Naples, Italy
Marc GH Besselink, the Netherlands
Markus Buechler, Heidelberg, Germany
Isidoro Di Carlo, Catania, Italy
Ross Carter, UK
William C Chapman, USA
Ravi Chari, Nashville, USA
Miin-Fu Chen, Tao-yuan, Taiwan
Michael Choti, Baltimore, USA
John Christein, USA
Chris Christophi, Melbourne, Australia
Pierre-Alain Clavien, Zurich, Switzerland
Jose Eduardo Cunha, Sao Paolo, Brazil
Cornelius CH Dejong, the Netherlands
Eduardo de Santibannes, Buenos Aires, Argentina
Christos Dervenis, Athens, Greece
Joseph Espat, Providence, USA
Oliver Farges, France
Laureano Fernández-Cruz, Barcelona, Spain
Craig Fischer, USA
Yuman Fong, New York, USA
Andrea Frilling, London, UK
Steve Gallinger,Toronto, Canada
Jean-François Gigot, Brussels, Belgium
Hein Gooszen, Utrecht, the Netherlands
Dirk Gouma, Amsterdam, the Netherlands
Paul Greig, Canada
Ulf Haglund, Sweden
Scott Helton, New Haven, USA
Alan W. Hemming, USA
Mike Henderson, Cleveland, USA
Thomas J Howard, USA
Jacob Izbicki, Hamburg, Germany
Palepu Jagannath, Mumbai, India
William Jarnagin, USA
Norihiro Kokudo, Japan
M. Krawczyk, Poland
Jake Krige, Cape Town, South Africa
Paul Lai, Hong Kong, China
Javier C Lendoir, Argentina
David Mahvi, Chicago, USA
Masatoshi Makuuchi, Tokyo, Japan
Robert Martin, USA
John McCall, New Zealand
Miguel A Mercado Diaz, Mexico
David Nagorney, Rochester, USA
Robert Padbury, Adelaide, Australia
Theodore Pappas, Durham, UK
Rowan Parks, Edinburgh, UK
Wright Pinson, Nashville, USA
Henry Pitt, Indiana, USA
Alfonso Principe, Bologna, Italy
Merv Rees, Basingstoke, UK
Miroslav Ryska, Prague, Czech Republic
Richard Schulick, USA
Marcus Selzner, Toronto, Canada
Tadahiro Takada, Tokyo, Japan
Thomas van Gulik, Amsterdam, the Netherlands
Charles Vollmer, USA
John Windsor, Auckland, New Zealand
| 
